0.3651
전일 마감가:
$0.3497
열려 있는:
$0.3498
하루 거래량:
1.20M
Relative Volume:
0.58
시가총액:
$21.41M
수익:
-
순이익/손실:
$-98.79M
주가수익비율:
-0.1117
EPS:
-3.27
순현금흐름:
$-51.66M
1주 성능:
-43.40%
1개월 성능:
+20.46%
6개월 성능:
-89.54%
1년 성능:
-90.19%
Relmada Therapeutics Inc Stock (RLMD) Company Profile
명칭
Relmada Therapeutics Inc
전화
646 876 3459
주소
2222 PONCE DE LEON BLVD. 3RD FLOOR, CORAL GABLES, NY
RLMD을(를) 다른 주식과 비교
주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
---|---|---|---|---|---|---|
3.03 | 0 | 0 | 0 | 0 | 0.00 | |
![]()
GOODO
Gladstone Commercial Corporation
|
20.23 | 372.90M | 0 | 0 | 0 | 0.00 |
![]()
PSNYW
Polestar Automotive Holding Uk
|
0.1601 | 355.59M | 2.07B | -1.42B | -1.37B | -0.6765 |
![]()
MOBBW
Mobilicom Limited Warrants
|
0.2199 | 318.40M | 0 | 0 | 0 | 0.00 |
![]()
JUNE
Dhandho Junoon Etf
|
11.50 | 211.65M | 0 | 0 | 0 | 0.00 |
![]()
SHMD
Schmid Group N V
|
4.00 | 156.75M | 0 | 0 | 0 | 0.00 |
Relmada Therapeutics Inc Stock (RLMD) Upgrades & Downgrades
날짜 | 액션 | 분석자 | 등급 변경 |
---|---|---|---|
2024-12-05 | 다운그레이드 | Mizuho | Outperform → Neutral |
2024-09-17 | 업그레이드 | Jefferies | Hold → Buy |
2024-06-05 | 다운그레이드 | Goldman | Neutral → Sell |
2022-10-14 | 다운그레이드 | Goldman | Buy → Neutral |
2022-10-14 | 다운그레이드 | Guggenheim | Buy → Neutral |
2022-10-14 | 다운그레이드 | Truist | Buy → Hold |
2022-10-13 | 다운그레이드 | Oppenheimer | Outperform → Perform |
2021-11-18 | 개시 | Mizuho | Buy |
2021-05-20 | 재개 | Goldman | Buy |
2020-10-28 | 다운그레이드 | Goldman | Buy → Neutral |
2020-07-14 | 개시 | Oppenheimer | Outperform |
2020-05-04 | 개시 | SunTrust | Buy |
2020-04-21 | 개시 | Goldman | Buy |
2020-01-27 | 개시 | Jefferies | Buy |
2020-01-10 | 개시 | SVB Leerink | Outperform |
2019-12-16 | 개시 | Guggenheim | Buy |
모두보기
Relmada Therapeutics Inc 주식(RLMD)의 최신 뉴스
Relmada Therapeutics Inc expected to post a loss of 31 cents a shareEarnings Preview - TradingView
Chief Executive Officer TRAVERSA SERGIO acquire 51,407 shares of Relmada Therapeutics Inc [RLMD] - knoxdaily.com
It makes sense and dollars to buy Relmada Therapeutics Inc (RLMD) stock - Sete News
AbbVie’s Rinvoq is approved in giant cell arteritis; Relmada shares bladder cancer data - Endpoints News
Market Insights: Relmada Therapeutics Inc (RLMD)’s Notable Drop of -44.64, Closing at 0.36 - DWinneX
Relmada Therapeutics (RLMD) Reports Promising Phase 2 Results fo - GuruFocus
Relmada Therapeutics Presents Positive Initial Phase 2 NDV-01 Da - GuruFocus
Taking a Closer Look At Relmada Therapeutics Inc (RLMD) Following Its Recent Trade - knoxdaily.com
Relmada Therapeutics Reports 'Positive' Phase 2 Data for Bladder Cancer Treatment - marketscreener.com
Relmada Therapeutics, Inc. Presents Positive Initial Phase 2 NDV-01 Data at AUA2025 - marketscreener.com
Relmada reports strong Phase 2 results for bladder cancer drug By Investing.com - Investing.com Canada
Relmada reports strong Phase 2 results for bladder cancer drug - Investing.com
SEC Form 424B5 filed by Relmada Therapeutics Inc. - Quantisnow
Relmada Therapeutics (RLMD) Presents Positive Initial Phase 2 NDV-01 Data - StreetInsider
Relmada Therapeutics Presents Positive Initial Phase 2 NDV-01 Data at AUA2025 - Quantisnow
Breakthrough: Relmada's New Bladder Cancer Drug Achieves 90% Disease-Free Rate in Phase 2 Trial - Stock Titan
Relmada Therapeutics Inc: Rising -85.57% from 52-Week Low, Can the Stock Stay Afloat? - investchronicle.com
Relmada Therapeutics (RLMD) to Discuss NDV-01 Phase 2 Study Resu - GuruFocus
UPDATE -- Relmada Therapeutics To Present NDV-01 Data at AUA2025 - GuruFocus
Relmada Therapeutics Presents NDV-01 Data at AUA2025 Conference for High-Risk Non-Muscle Invasive Bladder Cancer - Nasdaq
Groundbreaking Bladder Cancer Treatment Data: Relmada's NDV-01 Takes Center Stage at AUA2025 - Stock Titan
Press Release Distribution & PR Platform - ACCESS Newswire
Stock Performance Spotlight: Relmada Therapeutics Inc (RLMD) Ends the Day at 0.74, Up by 6.86 - DWinneX
Relmada Therapeutics to Host KOL Event on Phase 2 NDV-01 Data - The Manila Times
Bridgeline Digital Secures Elite SOC 2 Type II Certification: What This Means for Enterprise Security - Stock Titan
Take off with Relmada Therapeutics Inc (RLMD): Get ready for trading - Sete News
RLMD’s price-to-free cash flow ratio: What it means for investors - uspostnews.com
Relmada Therapeutics Inc (RLMD) receives a Neutral rating from Mizuho - knoxdaily.com
RLMD Stock: A Comprehensive Analysis and Forecast - investchronicle.com
Relmada Therapeutics (NASDAQ:RLMD) Trading Down 0.8% – Should You Sell? - Defense World
Relmada Therapeutics To Present NDV-01 Data at AUA2025 | RLMD St - GuruFocus
UPDATE — Relmada Therapeutics To Present NDV-01 Data at AUA2025 - TradingView
Revolutionary Cancer Therapy NDV-01 Data: Game-Changing Results Coming to AUA2025 - Stock Titan
Relmada Therapeutics To Present NDV-01 Data at AUA2025 - Yahoo Finance
Relmada outlines plans for NDV-01 Phase 2 results presentation and sepranolone development - MSN
Relmada Therapeutics, Inc. (NASDAQ:RLMD) Q4 2024 Earnings Call Transcript - Insider Monkey
Relmada Therapeutics: Strategic Acquisitions and Pipeline Progress - TipRanks
Relmada Therapeutics pivots from psilocybin to cancer, neurological disorders - Crain's Chicago Business
Relmada Therapeutics Inc (RLMD) Q4 2024 Earnings Call Highlights: Strategic Acquisitions and ... - Yahoo
Relmada Therapeutics Inc (RLMD) Q4 2024 Earnings Call Highlights - GuruFocus
Relmada Therapeutics Reports 2024 Financial Results and Strategic Progress - TipRanks
Earnings call transcript: Relmada Therapeutics Q4 2024 sees improved EPS By Investing.com - Investing.com South Africa
Earnings call transcript: Relmada Therapeutics Q4 2024 sees improved EPS - Investing.com India
RELMADA THERAPEUTICS Earnings Results: $RLMD Reports Quarterly Earnings - Nasdaq
Relmada Therapeutics Inc reports results for the quarter ended December 31Earnings Summary - TradingView
Relmada Therapeutics Reports Fourth Quarter and Full Year 2024 Results and Provides Business Update - The Manila Times
Relmada Cuts Losses by 25%: Key Pipeline Programs Hit Critical Phase in 2025 - Stock Titan
Relmada Therapeutics Inc -On March 24, Enters Exclusive License Agreement With Trigone PharmaSEC Filing - MarketScreener
Insights Ahead: Relmada Therapeutics's Quarterly EarningsRelmada Therapeutics (NASDAQ:RLMD) - Benzinga
Mizuho maintains Relmada stock neutral with $1.00 target By Investing.com - Investing.com Canada
Relmada Therapeutics to Report Fourth Quarter 2024 Financial Results on Thursday, March 27, 2025 - Quantisnow
Relmada Therapeutics Inc (RLMD) 재무 분석
매출
순이익
현금흐름
주당 순 이익
자본화:
|
볼륨(24시간):